AMG-517 is a potent and selective inhibitor targeting the KRAS G12C mutation, a specific genetic alteration commonly found in certain cancers. It works by irreversibly binding to the mutated KRAS protein, locking it in an inactive state, thereby blocking signaling pathways that drive tumor growth. This compound has shown significant promise in oncology, particularly in non-small cell lung cancer (NSCLC) and colorectal cancer where the KR7AS G12C mutation is prevalent. In clinical settings, AMG-517 is being evaluated for its ability to induce tumor regression and improve progression-free survival in patients with advanced solid tumors. Its development represents a breakthrough in targeting previously "undruggable" KRAS mutants, offering a tailored therapeutic approach in precision medicine.